tag:blogger.com,1999:blog-7923005810906159036.post1479439030935287324..comments2024-03-05T15:48:10.814+00:00Comments on IP finance: Branded Generics; did The Economist Get It Right?Anne Fairpohttp://www.blogger.com/profile/02579190868405783459noreply@blogger.comBlogger1125tag:blogger.com,1999:blog-7923005810906159036.post-23081340136563708052009-09-01T11:07:24.427+01:002009-09-01T11:07:24.427+01:00When a patent on a pharmaceutical product expires ...When a patent on a pharmaceutical product expires it is customary for the original patent owner to continue to market the product under is brand/trade mark name. For non-prescription medicines the public tend to continue to buy the branded product as they seldom know the generic name. Few pharmacists advise their customers of potential cost saving by buying genrics as these have a lower profit margin. Sales of "Panadol" brand paracetamol and "Aspro" brand aspirin flourish. In the UK the BNF ensures that doctors do not fall into this trap; they must prescribe the generic if available.Anonymousnoreply@blogger.com